Diabetes Technology Update

Peter Hammond Consultant Endocrinologist Harrogate District Hospital




### **Declaration for Peter Hammond**


I have the following financial interest or relationship/s to disclose with regard to the subject matter of this presentation:


Consulting fees: Medtronic, Abbott





## Hybrid Closed Loop Systems






Continuous subcutaneous insulin infusion (CSII)





## DERMIS – skin inflammation with CSII



■ Control Site ■ Recovery Site ■ Current Site

## CSII: improving reliability






Butterfield RD & Sims NM IEEE Open J Eng Med Biol 2024;5:595-599.



## Hybrid Closed Loop Systems







#### Hybrid Closed Loop (HCL) Systems Comparison Chart



Diabetes Specialist Nuse Forum UK	Medtronic	Tandem	Advanced Therapeutics	Ypsomed	Insulet
HCL algorithm	SmartGuard	Control IQ	CamAPS FX	mylife Loop (mylife CamAPS FX)	SmartAdjust
Location of algorithm	Pump-integrated	Pump-integrated	App based (Android)	App based (Android)	Pod-integrated
Pump	Medtronic 780g	T-slim X2	DANA-i	mylife YpsoPump	Omnipod 5
Pump type	Tethered (tubed)	Tethered (tubed)	Tethered (tubed)	Tethered (tubed)	Patch (tubeless)
Continuous glucose monitor (CGM)	Guardian 4 (no calibration)	Dexcom G6, Dexcom G7	Dexcom G6	Dexcom G6, FreeSyle Libre 3	Dexcom G6, FreeStyle Libre 2 Plus
Control & bolus delivery operation	Pump	Pump	Android smartphone	Android smartphone	Omnipod 5 Controller (PDM)
Pump charging mechanism	AA battery	Rechargeable	AAA battery	AAA battery	Battery within each pod Controller is rechargeable
Target glucose	5.5, 6.1 or 6.7 mmol/L (default 5.5)	6.25-8.9 mmol/L	Customisable from 4.4 to 11.1 (default 5.8)	Customisable from 4.4 to 11.1 (default 5.8)	6.1, 6.7, 7.2, 7.8, or 8.3 mmol/L
Exercise mode target glucose	8.3 mmols/L	7.8-8.9 mmol/L	No specific target. Ease off mode can be used for exercise	No specific target. Ease off mode can be used for exercise	8.3 mmol/L & less insulin delivery
Sleep mode target glucose	No	6.25-6.7 mmols/L	Customisable glucose target can be adjusted overnight	Customisable glucose target can be adjusted overnight	Customisable glucose target or exercise feature (see above)
Bolus calculator based on	CGM value, glucose trend data and bolus calculator settings	CGM value only with bolus calculator settings	CGM value only with bolus calculator settings	CGM value only with bolus calculator settings	CGM value, glucose trend data and bolus calculator settings
Automated correction bolus settings	If predictive glucose > 6.7 mmols/L and if max basal rate is reached	If predicted glucose in 30 mins >10 mmols/L & increasing/max delivery is reached	Incorporated into continuous insulin delivery. Adjusts insulin delivery every 8-12 minutes	Incorporated into continuous insulin delivery. Adjusts insulin delivery every 8-12 minutes	Automated micro-boluses every 5 mins. Plus user initiated correction bolus
Active insulin time	Adjustable	Not adjustable (set at 5 hrs)	Adjustable	Adjustable	Adjustable
Set up requirements	Basal rates, ICR, ISF & AIT	TDD, body weight, basal rates, ICR & ISF	TDD & body weight	TDD & body weight	Basal rates, ICR, ISF & AIT
Learning mechanisms	Uses TDD over past 2-6 days. Requires 48 hours of manual mode to learn user profile	Uses body weight & TDD. Predicts glucose 30 mins ahead	Overall insulin needs, diurnal, post meal	Overall insulin needs, diurnal, post meal	Adapts with each pod using previous TDDs. Predicts glucose 60 mins ahead
Remote monitoring for parents/ carers	Glucose and insulin data via CareLink Connect app	Glucose via Dexcom follow app	Glucose via Dexcom follow app	Glucose and insulin data via 'companion' in mylife CamAPS FX app	Glucose via Dexcom follow app if using G6
Data share with HCPs	CareLink (via app in real-time)	Glooko (download needed)	Glooko (real-time)	Glooko (real-time)	Glooko (real-time)
Minimum and maximum daily dose	8-250 units per day	10-100 units per day	5-350 units	5-350 units	Min 5 units per day Min 85 units to activate pod
Pump capacity	300 units	300 units	300 units	160 units	200 units
Insulin compatibility	NovoRapid & Humalog	NovoRapid & Humalog	Any rapid and ultra-rapid acting	NovoRapid, Humalog, Fiasp, Apidra & Lyumjev	NovoRapid, Humalog & Admelog
Licensed in pregnancy	No	No	Yes	Yes	No
Age Range	7-80 years	6 years & over	1 years & over	1 years & over	2 years & over
Demo pump app/simulator	Yes	Yes	?	Yes	Yes


ICR – insulin carbohydrate ratio ISF – insulin sensitivity factor TDD – total daily dose of insulin AIT – active insulin time For availability of systems approved by NHS England: www.supplychain.nhs.uk/product-information/contract-launch-brief/insulin-pumps-and-associated-products

Version 4.0 May 2024: Adapted for health care professionals from Tim Street's Hybrid closed loop systems






## AHCL in T2DM






## Towards restoring "normal" glycaemia







## Fully Closed Loop – CAM APS





## Dual hormone HCL: RCT in adolescents






### Dual hormone RCT







https://www.inredadiabetic.nl/en/discover-the-ap/

van Bon AC et al. Lancet Digit Health 2024;6: e272-80







# Continuous glucose sensing



#### **Real-time Continuous Glucose Monitoring Systems Comparison Chart**

<b>Diabetes Specialist</b>	
Nurse Forum UK	H

Diabetes Specialist  Nurse Forum UK	FreeStyle Libre 2	FreeStyle Libre 2 Plus	FreeStyle Libre 3	Dexcom ONE	Dexcom ONE+	GlucoRx AiDEX
Real-time CGM	Yes*	Yes*	Yes	Yes	Yes	Yes
MARD (%)	9.2	8.2	7.8	9.0	8.2	9.1
Published accuracy data	Yes (T1 n=133)	No (T1=128)	Yes (T1 n=83)	Yes (T1 n=260)	Yes (T1 n=257)	Yes (T1 n=14)
RCT data	Yes	Yes (FSL/FSL2)	Yes (FSL/FSL2)	Yes (G4/5/6)	No	No
Stand-alone use	Yes	Yes	Yes	Yes	Yes	Yes
Pump/hybrid closed loop (HCL) compatibility	No	Omnipod 5	YpsoPump	No	No	No
Sensor life	14 days	15 days	14 days	10 days	10 days +12 hr grace period	14 days
Sensor warm up time	60 mins	60 mins	60 mins	120 mins	Up to 30 mins	60 mins
Separate transmitter	No	No	No	Yes	No	Yes
Transmitter Life	N/A	N/A	N/A	3 months	N/A	4 years
Smartphone app	LibreLink	LibreLink	Libre 3	Dexcom One	Dexcom One +	GlucoRx AiDEX
Reader available	Yes	Yes	Yes	Yes	Yes	No
Capillary glucose calibration	No	No	No	No	No	No
High & low alarms	Yes	Yes	Yes	Yes	Yes	Yes
Predictive alarms	No	No – stand-alone use	No - stand-alone use Yes - HCL use	No	No	No
Smart pen data connection	NovoPen 6 & Echo Plus	NovoPen 6 & Echo Plus	No	NovoPen 6 & Echo Plus ▲ SoloSmart pen cap ▲	NovoPen 6 & Echo Plus ▲ SoloSmart pen cap ▲	No
Data share HCP	LibreView	LibreView	LibreView	Clarity	Clarity	CGM Viewer
Data share friends/family app	LibreLinkUp	LibreLinkUp	LibreLinkUp	N/A	Dexcom Follow	GlucoRx AiDEX
UK approved wearable site	Back upper arm	Back upper arm	Back upper arm	Abdomen Back upper arm Buttocks <sup>+</sup>	Abdomen Back upper arm Buttocks **	Abdomen Back upper arm



= available via NHS supply chain

Version 7.0 June 2024



<sup>\*</sup> When using LibreLink app on smartphone. 'Scanning' still required with reader device

<sup>\*\*</sup> Different version of Guardian 4 sensor required

<sup>▲</sup> via Glooko

<sup>+ 2-17</sup> years old as per manufacturers' guidelines.

<sup>++ 2-6</sup> years old as per manufacturers' guidelines

<sup>+++ 7-17</sup> years old as per manufacturers' guidelines.

#### **Real-time Continuous Glucose Monitoring Systems Comparison Chart**



Diabetes Specialist  Nurse Forum UK	Dexcom G6	Dexcom G7	Medtronic Guardian 4	Medtronic Simplera	Medtrum Touch Care Nano
Real-time CGM	Yes	Yes	Yes	Yes	Yes
MARD	9.0	8.2	10.6	10.2	9.1
Published accuracy data	Yes (T1 n=260)	Yes (T1 n=257)	Yes	Yes	Yes (T1 n=10)
RCT data	Yes	No	No	No	No
Stand-alone use	Yes	Yes	Yes	Yes	Yes
Pump/hybrid closed loop compatibility	Tandem T:slim DANA-i YpsoPump Omnipod 5	Tandem T:slim	MiniMed 780G **	No	Touch Care Nano pump (Automode)
Sensor life	10 days	10 days +12 hr grace period	7 days	7 days	10-14 days
Sensor warm up time	120 mins	Up to 30 mins	120 mins	120 mins	30 mins
Separate transmitter	Yes	No	Yes	No	Yes
Transmitter Life	3 months	N/A	12 months	N/A	12 months
Smartphone app	Dexcom G6	Dexcom G7	MiniMed mobile	Simplera	EasySense
Reader available	Yes	Yes	No	No	Yes
Capillary glucose calibration	No	No	No	No	No
High & low alarms	Yes	Yes	Yes	Yes	Yes
Predictive alarms	Yes	Yes	Yes	Yes	Yes
Smart pen data connection	NovoPen 6 & Echo Plus ▲ SoloSmart pen cap ▲	NovoPen 6 & Echo Plus ▲ SoloSmart pen cap ▲	No	Medtronic InPen	No
Data share HCP	Clarity	Clarity	CareLink	CareLink	EasyView
Data share friends/family app	Dexcom Follow	Dexcom Follow	CareLink Connect	CareLink Connect	EasyFollow
UK approved wearable site	Abdomen Back upper arm Buttocks <sup>†</sup>	Abdomen Back upper arm Buttocks <sup>†</sup>	Abdomen Back upper arm Buttocks +++	Back upper arm Buttocks <sup>+</sup>	Abdomen Back upper arm

<sup>=</sup> available on prescription (FP10)

= available via NHS supply chain

Version 7.0 June 2024



<sup>\*</sup> Using LibreLink app on smartphone. 'Scanning' still required with reader device

<sup>\*\*</sup> Different version of Guardian 4 sensor required

<sup>▲</sup> via Glooko

<sup>+ 2-17</sup> years old as per manufacturers' guidelines.

<sup>++ 2-6</sup> years old as per manufacturers' guidelines

<sup>+++ 7-17</sup> years old as per manufacturers' guidelines.

## Steno2Tech: CGM vs SMBG in T2DM





## Continuous ketone monitoring

## \*\*\*IMPENDING DKA\*\*\* Treat as follows or per clinician instructions:

- Ingest 15 -30g rapidly absorbed carbohydrate and a large glass of water hourly
- Administer rapid-acting insulin based on carbohydrate intake hourly
- Monitor ketone levels until ketones 
   0.6 mmol/L and symptoms resolve
- Monitor glucose to avoid hypoglycemia
- Seek medical attention if levels and/or symptoms persist





#### Stay in Your Best ZONE

Do you know there are 4 different ketosis states? Each state renders different benefits. Picking the right one is crucial to achieving your goals.

#### Nutritional Ketosis (0.5-1.0 mmol/L)

- improvements in energy and mental calrity
- Appetite control, reduction of cravings

#### Optimal Ketosis (1.0-2.0 mmol/L)


- Best for consistent and noticeable fat loss
- Improved metabolic health
- Increased physical endurance

#### High Ketosis (2.0-3.0 mmol/L)

- Therapeutic benefits for managing mental conditions
- Enhanced atheletic performance
- Reduced inflammation and risk of chronic diseases

#### Deep Ketosis (≥ 3.0 mmol/L)

- Maximized mental clarity
- May mitigate the growth of certain cancers
- Potentially slowing the progression of mental diseases



#### Stay in Ketosis Longer, with Real-Time Insights



Optimize Your Workouts Discover how different exercises affect your metabolis. Discover the best foods that help you multiple kelosis.



Optimize Your Nutrition




Optimize Your Sleep

Understand your betime Too believe during sleep.








## Technology Use in Hospital Settings

Real-time Continuous Glucose Monitoring in the Intensive Care Unit: The Fifth Vital Sign


Patham B et al. *Diabetes Care* 2024;47:924-6.

## CSII + CGM for in-patient glycaemic control





## TiR and mortality for critically ill in-patients





# Benefits of technology in older people with diabetes

- Maltese et al (2024) Diabetologia
   DOI 10.1007/s00125-024-06240-2
- ©The Authors 2024. Distributed under the terms of the CC BY 4.0 Attribution License


(http://creativecommons.org/licenses/by/4.0/)












- E-literacy
- Cognition
- Mood
- · Dexterity
- · Visual acuity



- Hearing
- Physical function and frailty
- · Living setting
- · Social context



#### Potential positive outcomes (benefits)

Regression or reduced progression of frailty



Reduced risk of hospitalisation



Reduced risk of cognitive impairment and its progression



Reduced rate of call-outs for hyper- or hypoglycaemia



Improved quality of life



## Key barriers to the use of technology in older people

- Maltese et al (2024) Diabetologia
   DOI 10.1007/s00125-024-06240-2
- ©The Authors 2024. Distributed under the terms of the CC BY 4.0 Attribution License

(http://creativecommons.org/licenses/by/4.0/)



## Case report of AHCL in 89 year old with early dementia


**Table 1** Comparison of indices of continuous glucose monitoring using an insulin pump and carbohydrate counting methods

Mode	Manual	HCL
Carb counting	(-)	(+)
TIR (%)	41	70
TAR (%)	59	30
TBR (%)	0	0
Mean glucose (mg/dL)	$209 \pm 74$	$162 \pm 55$
TDD (U)	27.1	28.6
Basal (U)	10.4	13.3
Bolus (U)	16.7	15.3
Glycoalbumin (%)	29.2	26.5
HbA1c (%)	7.6	6.9

*Note*: Data for the manual mode was extracted for 4 weeks just before the carbohydrate counting was started, and data for the HCL mode was extracted for 4 weeks, 5–9 weeks after starting the HCL mode.



## Sarcopenia and TiR





#### Research questions

What is the impact of CGM, insulin pumps and AID systems on geriatric syndromes, life expectancy and risk of hospitalisation in older people?

How can we implement diabetes technology with other technologies?


Is diabetes technology cost-effective and safe for use in care homes?

Which CGM metrics should we aim for, based on level of frailty?

Can pumps and AID systems be safely used in frail older people and in those with dementia?

Should older individuals with diabetes being considered for technology be managed collaboratively with other teams such as geriatric or frailty teams?

Would the use of geriatric tools (e.g. Comprehensive Geriatric Assessment [CGA]) help to overcome barriers to use of diabetes technology?



#### Potential effects on clinical care

Improvement in quality of life and life expectancy

Reduction in rates of hospital admissions and emergency department attendances

Improvement in physical function and cognition

Increase in costeffectiveness of care

# Research questions related to diabetes technology in older people


- Maltese et al (2024) Diabetologia DOI 10.1007/s00125-024-06240-2
- ©The Authors 2024. Distributed under the terms of the CC BY 4.0 Attribution License

(<a href="http://creativecommons.org/licens">http://creativecommons.org/licens</a> es/by/4.0/)

## Summary



Hybrid closed loop technology is established as the insulin delivery system of choice for most people with T1DM



Fully-closed loop systems are effective but their superiority is questionable and the place of bi-hormonal systems uncertain



There will continue to be improvements in the component parts of the HCL systems around reliability and usability



Supporting older people to get the most out of diabetes technology is a priority